Polymorphism in the beta(1)-adrenergic receptor gene and hypertension
Summary
This summary is machine-generated.Individuals with two copies of the Arg389 allele in the beta(1)-adrenergic receptor gene have a higher risk of developing hypertension. This genetic variant is linked to increased blood pressure and heart rate.
Area Of Science
- Pharmacogenomics
- Cardiovascular Genetics
Background
- The beta(1)-adrenergic receptor gene (ADRB1) plays a crucial role in cardiovascular regulation.
- Specific polymorphisms, Arg389Gly and Ser49Gly, influence receptor function and may be associated with hypertension.
- The Arg389 variant exhibits higher in vitro adenylate cyclase activity compared to the Gly389 variant.
Purpose Of The Study
- To investigate the association between ADRB1 Arg389Gly and Ser49Gly polymorphisms and hypertension in a Scandinavian population.
- To determine if specific genotypes correlate with increased risk or severity of hypertension.
Main Methods
- A case-control study involving 292 hypertensive patients and 265 healthy controls.
- A sibling-pair study with 102 nondiabetic, medication-free sibling pairs discordant for the Arg389Gly polymorphism.
- Comparison of allele and genotype frequencies, blood pressure, and heart rate between groups.
Main Results
- Homozygosity for the Arg389 allele was significantly associated with hypertension (OR=1.9, P=0.0005) in the case-control study.
- Arg389 homozygous siblings exhibited higher diastolic blood pressure (P=0.003) and heart rate (P=0.02) compared to Gly389 carriers.
- The Ser49Gly polymorphism showed no association with hypertension.
Conclusions
- The Arg389 allele of the beta(1)-adrenergic receptor gene is a risk factor for hypertension.
- Individuals homozygous for Arg389 are at an increased risk of developing hypertension.
- The ADRB1 Arg389Gly polymorphism is a significant genetic determinant of hypertension risk.
View abstract on PubMed